

# Scott C Morgan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5538960/publications.pdf>

Version: 2024-02-01

51  
papers

2,114  
citations

471509

17  
h-index

233421

45  
g-index

51  
all docs

51  
docs citations

51  
times ranked

3083  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 74-79.	3.9	6
2	Association of Short-Term Patient-Reported Outcomes With Long-Term Oncologic Outcomes in Localized Prostate Cancer Patients Treated With Radiation Therapy and Androgen Deprivation Therapy in a Randomized Controlled Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 880-889.	0.8	0
3	Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 192.e1-192.e9.	1.6	6
4	Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study. <i>BJU International</i> , 2022, 3, 383-391.	1.3	3
5	Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. <i>European Urology</i> , 2022, 5, 494-502.	5.4	21
6	Impact of Concomitant Medications on Biochemical Outcome in Localised Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy. <i>Clinical Oncology</i> , 2021, 33, 181-190.	1.4	9
7	Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 136-144.	1.6	52
8	Unenhanced MRI of the abdomen and pelvis for surveillance of patients with stage 1 testicular cancer post-radical orchiectomy. <i>Abdominal Radiology</i> , 2021, 46, 1157-1162.	2.1	3
9	Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab082.	2.9	17
10	Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 1274-1305.	1.6	67
11	Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1041-1047.	3.9	13
12	Impact of Treating Physician on Radiation Therapy Related Severe Toxicities in Men with Prostate Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, e292-e300.	2.1	2
13	Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, 353-358.	0.6	2
14	Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada. <i>Cancers</i> , 2021, 13, 2844.	3.7	10
15	A Review on the Current Treatment Paradigm in High-Risk Prostate Cancer. <i>Cancers</i> , 2021, 13, 4257.	3.7	10
16	Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. <i>European Urology</i> , 2021, 80, 693-700.	1.9	65
17	Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 593-601.	1.6	45
18	Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada. <i>Canadian Urological Association Journal</i> , 2020, 14, E588-E593.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Impact of Sequencing of Androgen Suppression and Radiation Therapy on Testosterone Recovery in Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1179-1188.	0.8	10
20	Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses. , 2020, 47, E86-E106.		10
21	Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?. Current Urology Reports, 2019, 20, 53.	2.2	11
22	A A Canadian consensus forum on the management of patients with advanced prostate cancer. Canadian Urological Association Journal, 2019, 14, E137-E149.	0.6	15
23	Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncology, The, 2019, 20, 1531-1543.	10.7	362
24	Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database. Clinical Oncology, 2019, 31, 630-636.	1.4	19
25	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline Summary. Journal of Oncology Practice, 2019, 15, 50-54.	2.5	2
26	Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer. Canadian Urological Association Journal, 2019, 13, 420-426.	0.6	9
27	Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice. Journal of Medical Imaging and Radiation Sciences, 2019, 50, S26-S30.	0.3	2
28	External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet, The, 2019, 394, 2165-2172.	13.7	279
29	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. Journal of Urology, 2019, 201, 528-534.	0.4	57
30	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. Journal of Clinical Oncology, 2018, 36, 3411-3430.	1.6	118
31	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Practical Radiation Oncology, 2018, 8, 354-360.	2.1	151
32	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. Journal of Urology, 2018, , .	0.4	16
33	Radiotherapy with radical cystectomy for bladder cancer: A systematic review and meta-analysis. Canadian Urological Association Journal, 2018, 12, 351-360.	0.6	8
34	Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis. BJU International, 2018, 122, 744-753.	2.5	60
35	Reducing errors in prostate tracking with an improved fiducial implantation protocol for CyberKnife based stereotactic body radiotherapy (SBRT). Journal of Radiosurgery and SBRT, 2018, 5, 217-227.	0.2	3
36	Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer. Annals of Internal Medicine, 2017, 167, 341.	3.9	35

#	ARTICLE	IF	CITATIONS
37	Hemostatic radiotherapy in advanced bladder cancer: a single-institution experience. Journal of Radiation Oncology, 2017, 6, 379-385.	0.7	1
38	Multiparametric magnetic resonance imaging for pre-treatment local staging of prostate cancer: A Cancer Care Ontario clinical practice guideline. Canadian Urological Association Journal, 2016, 10, 332.	0.6	16
39	Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Clinical Oncology, 2016, 34, 2182-2190.	1.6	285
40	Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. Canadian Urological Association Journal, 2016, 10, 90.	0.6	6
41	Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses. Systematic Reviews, 2015, 4, 114.	5.3	16
42	Multivariate modelling of prostate cancer combining magnetic resonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters. European Radiology, 2015, 25, 1247-1256.	4.5	24
43	Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters. British Journal of Radiology, 2014, 87, 20130813.	2.2	28
44	Radiotherapy after Radical Prostatectomy: Treatment Recommendations Differ between Urologists and Radiation Oncologists. PLoS ONE, 2013, 8, e79773.	2.5	15
45	Postoperative Radiotherapy After Radical Prostatectomy: Adjuvant or Salvage?. Current Cancer Therapy Reviews, 2011, 7, 167-175.	0.3	0
46	Local treatment of metastatic cancerâ€”killing the seed or disturbing the soil?. Nature Reviews Clinical Oncology, 2011, 8, 504-506.	27.6	38
47	Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?. Expert Review of Anticancer Therapy, 2009, 9, 939-951.	2.4	8
48	Mobilization of Circulating Vascular Progenitors in Cancer Patients Receiving External Beam Radiation in Response to Tissue Injury. International Journal of Radiation Oncology Biology Physics, 2009, 75, 220-224.	0.8	13
49	Helical tomotherapy for locoregional irradiation including the internal mammary chain in left-sided breast cancer: Dosimetric evaluation. Radiotherapy and Oncology, 2009, 90, 99-105.	0.6	79
50	Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: A systematic review and meta-analysis. Radiotherapy and Oncology, 2008, 88, 1-9.	0.6	79
51	Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	4